Comparison of door-to-needle time of tenecteplase versus alteplase for acute ischemic stroke

Tenecteplase (TNK) is a genetically modified tissue plasminogen activator with greater fibrin specificity and a longer half-life that permits bolus administration compared to alteplase (tPA) which is administered as an IV bolus followed by a 60-min infusion [1]. Secondary outcomes included the inten...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of emergency medicine 2023-01, Vol.63, p.158-160
Main Authors: Dimova, Sidney Aviles, Levins, Elizabeth S., Bode, Emilie D., Mah, Nathan D.
Format: Article
Language:English
Subjects:
Drug stores
Emergency medical care
Fibrin
Humans
Ischemia
Ischemic Stroke
Optimization
Patients
Pharmacists
Stroke
t-Plasminogen activator
Tenecteplase - therapeutic use
Tissue Plasminogen Activator - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tenecteplase (TNK) is a genetically modified tissue plasminogen activator with greater fibrin specificity and a longer half-life that permits bolus administration compared to alteplase (tPA) which is administered as an IV bolus followed by a 60-min infusion [1]. Secondary outcomes included the intensive care unit (ICU) and hospital lengths of stay, discharge disposition, modified Rankin Scale (mRS) score change from baseline to discharge, and post-discharge follow-up, and the difference in National Institutes of Health Stroke Scale (NIHSS) scores from admission to discharge. Changing thrombolytics from tPA to TNK may not be a major contributor to shorter DTN times, with further reduction requiring multidisciplinary optimization of stroke workflow from all responders.Meetings This work has been presented previously in poster format at the 2021 Vizient Consortium Pharmacy Network Meeting (Virtual; December 1, 2021) and in platform format at the 2022 Northwestern States Residency Conference (Virtual; May 20, 2022).Funding This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.CRediT authorship contribution statement Sidney Aviles Dimova: Writing – original draft, Formal analysis, Data curation.
ISSN:0735-6757
1532-8171
DOI:10.1016/j.ajem.2022.09.030